A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

Zedula Special Drug Use Observational Study "Ovarian Cancer"

The main aim of this study is to check for side effects from treatment with niraparib.

The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with ovarian cancer will take capsules of niraparib (Zedula) once a day according to their clinic's standard practice. The study doctors will check for side effects from niraparib for 1 year after treatment starts.

Inclusion Criteria:

An individual who corresponds to any of the following:

• Ovarian cancer patients after initial chemotherapy (maintenance therapy)
• Patients with platinum antineoplastic drug sensitive recurrent ovarian cancer (maintenance therapy)
• Recurrent ovarian cancer with platinum-sensitive homologous recombination repair defects.

Exclusion Criteria:

Has a history of hypersensitivity to any of the ingredients of this drug.